[{"from": "human", "value": "What can you tell me about this molecule? [C][C][C][N][C][C@H1][Branch2][Ring1][#Branch1][C][C@H1][C@H1][Ring1][=Branch1][C][C][=C][Branch1][Ring2][C][Ring1][=Branch1][C][=Branch1][=Branch1][=C][C][=C][Ring1][#Branch1][O][N][S][=Branch1][C][=O][=Branch1][C][=O][N][Branch1][Ring1][C][C][C][C]"}, {"from": "gpt", "value": "The molecule is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis. Newer dopamine receptor agonists such as quinagolide and [DB00248] are shown to effectively inhibit prolactin secretion with improved efficacy over [DB01200]. These drugs are effective in patients who are intolerant or resistant to [DB01200]. Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer. It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States."}]